Ocugen, Inc.
About Ocugen, Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.4M
- Net income
- -$67.8M
- Total assets
- $43.5M
- Market cap
- $433.3M
- Operating margin
- -1425.7%
- Net margin
- -1537.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.4M
- Operating expenses
- $67.3M
- Operating income
- -$62.9M
- Income tax
- $0
- Net income
- -$67.8M
Balance sheet
- Total assets
- $43.5M
- Current assets
- $24.3M
- Total liabilities
- $55.7M
- Current liabilities
- $23.0M
- Shareholders’ equity
- -$12.2M
Cash flow
- Operating cash flow
- -$57.0M
- Investing cash flow
- -$311.0K
- Financing cash flow
- $17.3M
- Net cash flow
- -$39.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $433.3M
- Shares outstanding
- 364.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 3, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $67.8M in FY2025.
- Trading 52% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Ocugen, Inc..
Write a review
News about Ocugen, Inc.
News & sentiment via Polygon.io
